Understanding SMA and the Role of IVF
Spinal Muscular Atrophy (SMA) is a severe genetic disorder that affects the motor neurons in the spinal cord, leading to progressive muscle wasting and weakness. For couples who are carriers of the SMA gene mutation, the dream of starting a family often comes with significant anxiety regarding the health of their future children. Fortunately, advancements in reproductive technology—specifically IVF with PGT-M (Preimplantation Genetic Testing for Monogenic disorders)—have made it possible to significantly reduce the risk of passing this condition to the next generation.
In Istanbul, Turkey, our clinic specializes in complex genetic screening protocols, providing international patients with a safe and clinically proven pathway toward healthy biological parenthood.
What is SMA?
SMA is typically an autosomal recessive condition. This means that if both parents are asymptomatic carriers of a mutation in the SMN1 gene, there is a 25% chance in each pregnancy that the child will be born with the disease. SMA can vary in severity, ranging from Type 1 (onset in infancy, often life-threatening) to Type 4 (adult-onset). Because there is currently no absolute cure for SMA, prevention through genetic screening remains the most effective strategy for carrier couples.
IVF with PGT-M: A Solution for SMA Carriers
While traditional IVF is often associated with infertility treatment, it is also a powerful tool for preventing genetic diseases. When used for SMA, the process involves In Vitro Fertilization combined with highly specialized embryo testing.
The PGT-M Process
PGT-M (formerly known as PGD) is designed specifically to test embryos for a known single-gene disorder within a family. Here is how the process works for SMA carriers in our Istanbul center:
- Carrier Screening: Before beginning the IVF cycle, both partners undergo detailed genetic testing to confirm the specific mutations present.
- Ovarian Stimulation & Egg Retrieval: The mother undergoes a standard IVF stimulation protocol to produce multiple eggs.
- Fertilization: The eggs are fertilized in the laboratory using ICSI (Intracytoplasmic Sperm Injection) to ensure a high fertilization rate.
- Embryo Biopsy: Once the embryos reach the blastocyst stage (usually day 5 or 6), a few cells are carefully removed from the trophectoderm (the part that becomes the placenta).
- Genetic Analysis: These cells are analyzed in our state-of-the-art laboratory specifically for the SMA mutation.
- Selective Transfer: Only embryos that are identified as unaffected (either non-carriers or healthy carriers) are selected for transfer into the uterus.
The Benefits of Choosing PGT-M in Turkey
Turkey has emerged as a global hub for reproductive genetics. Patients choosing Istanbul for SMA-related IVF benefit from several key factors:
Advanced Laboratory Infrastructure
Testing for SMA requires high precision. Our labs utilize Next-Generation Sequencing (NGS) and linkage analysis to ensure the highest possible accuracy in identifying healthy embryos. This level of technology is essential to avoid "allelic dropout," a common technical challenge in genetic testing.
Affordability and Expertise
The cost of IVF with PGT-M testing in Turkey is significantly more competitive than in the US or UK, without compromising on medical standards. Our clinicians have extensive experience managing "at-risk" couples, providing both the technical expertise and the emotional support required during this journey.
Comprehensive Care
From the initial genetic counseling session to the final pregnancy test, we provide a holistic approach. We understand that patients traveling to Istanbul are looking for a seamless experience, and we coordinate all aspects of the travel and treatment plan.
Success Rates and Expectations
It is important to note that the success of IVF with PGT-M depends on several individual factors, including the mother’s age, ovarian reserve, and the number of healthy embryos available following genetic screening. Not every embryo created will be genetically healthy or suitable for transfer. However, for those embryos that are confirmed unaffected and successfully implanted, the risk of the child developing SMA is dramatically reduced (typically 98-99% accuracy).
The Importance of Genetic Counseling
Before proceeding with treatment, we recommend a comprehensive consultation with a genetic counselor. This ensures that you understand the specific inheritance patterns of SMA in your family and the limitations and possibilities of the PGT-M technology. Our team is dedicated to providing transparent information so you can make an informed decision for your family's future.
Frequently Asked Questions
Can PGT-M detect all types of SMA?
PGT-M is designed to detect the specific mutation identified in the parents. Since the vast majority of SMA cases are caused by the deletion of the SMN1 gene, PGT-M is highly effective. During your initial screening, our geneticists will confirm if your specific mutation can be tracked via our protocols.
Is the embryo biopsy safe?
Biopsying an embryo at the blastocyst stage is a routine procedure in modern IVF. While no procedure is without risk, current data suggests that removing a few cells from the part of the embryo that becomes the placenta does not negatively impact the development of the fetus or the health of the baby. We use highly skilled embryologists to ensure the procedure is performed with the utmost care.
What happens if all embryos carry the SMA gene?
In cases where both parents are carriers, there is a statistical 25% chance that an embryo will be affected. If a cycle results in only affected embryos, we will discuss the results with you in detail. Options may include a second stimulation cycle to increase the pool of embryos or exploring donor options, depending on your preferences and clinical situation.